| scholarly article | Q13442814 |
| P50 | author | Chang-Jer Wu | Q90362252 |
| P2093 | author name string | Yi-Lin Chan | |
| Hui-Wen Huang | |||
| Cheng-Fong Hong | |||
| Chiu-Yi Liu | |||
| P2860 | cites work | Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs | Q27641252 |
| Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells | Q27860926 | ||
| Coronavirus as a possible cause of severe acute respiratory syndrome | Q28200848 | ||
| Characterization of a novel coronavirus associated with severe acute respiratory syndrome | Q28202401 | ||
| Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate | Q28365532 | ||
| A novel coronavirus associated with severe acute respiratory syndrome | Q29617553 | ||
| The Genome sequence of the SARS-associated coronavirus | Q29619007 | ||
| A major outbreak of severe acute respiratory syndrome in Hong Kong | Q33347382 | ||
| RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells | Q34178401 | ||
| Modulation of HIV-1 replication by RNA interference | Q40721798 | ||
| Aminopeptidase N inhibitors and SARS | Q44434572 | ||
| P433 | issue | 1 | |
| P921 | main subject | SARSr-CoV | Q278567 |
| SARS-CoV-1 | Q85438966 | ||
| P304 | page(s) | 45-48 | |
| P577 | publication date | 2005-01-01 | |
| P1433 | published in | Antiviral Research | Q4775352 |
| P1476 | title | Inhibition of SARS-CoV replication by siRNA | |
| P478 | volume | 65 |
| Q30379545 | A Multiple siRNA-Based Anti-HIV/SHIV Microbicide Shows Protection in Both In Vitro and In Vivo Models |
| Q104475717 | A computational approach to design potential siRNA molecules as a prospective tool for silencing nucleocapsid phosphoprotein and surface glycoprotein gene of SARS-CoV-2 |
| Q52587809 | A review on current status of antiviral siRNA. |
| Q60638540 | Advancements in Nucleic Acid Based Therapeutics against Respiratory Viral Infections |
| Q37914065 | Antiviral RNAi: translating science towards therapeutic success |
| Q57103068 | Antiviral activity of nucleoside analogues against SARS-coronavirus (SARS-coV) |
| Q36376425 | Antiviral applications of RNAi for coronavirus |
| Q38815225 | Antivirals against animal viruses. |
| Q45422183 | Avian metapneumovirus phosphoprotein targeted RNA interference silences the expression of viral proteins and inhibits virus replication |
| Q34193942 | Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus |
| Q34513643 | Coronaviruses - drug discovery and therapeutic options. |
| Q36119173 | Development of antiviral therapy for severe acute respiratory syndrome. |
| Q90576464 | Drug targets for corona virus: A systematic review |
| Q41020916 | Effective inhibition of porcine epidemic diarrhea virus by RNA interference in vitro |
| Q40173552 | Effective inhibition of porcine transmissible gastroenteritis virus replication in ST cells by shRNAs targeting RNA-dependent RNA polymerase gene |
| Q99201268 | How can nanotechnology help to combat COVID-19? Opportunities and urgent need |
| Q98577409 | In Silico Design of siRNAs Targeting Existing and Future Respiratory Viruses with VirusSi |
| Q39519335 | In vitro inhibition of CSFV replication by multiple siRNA expression |
| Q33836655 | In vitro inhibition of porcine hemagglutinating encephalomyelitis virus replication with siRNAs targeting the spike glycoprotein and replicase polyprotein genes. |
| Q30230264 | Inhibition of SARS-CoV replication cycle by small interference RNAs silencing specific SARS proteins, 7a/7b, 3a/3b and S. |
| Q34312061 | Inhibition of Tulane virus replication in vitro with RNA interference |
| Q40306378 | Inhibition of measles virus and subacute sclerosing panencephalitis virus by RNA interference |
| Q39433525 | Inhibition of porcine hemagglutinating encephalomyelitis virus replication by short hairpin RNAs targeting of the nucleocapsid gene in a porcine kidney cell line |
| Q39616046 | Inhibition of viral hemorrhagic septicemia virus replication using a short hairpin RNA targeting the G gene |
| Q34531744 | Inhibition of viruses by RNA interference |
| Q30886121 | MicroRNome analysis unravels the molecular basis of SARS infection in bronchoalveolar stem cells |
| Q43280688 | Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies |
| Q98771881 | Molecular Pathogenesis, Immunopathogenesis and Novel Therapeutic Strategy Against COVID-19 |
| Q36801846 | Non-viral siRNA delivery to the lung |
| Q37338992 | Nucleic acids-based therapeutics in the battle against pathogenic viruses |
| Q34526756 | Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference |
| Q36404178 | Potential vaccines and post-exposure treatments for filovirus infections |
| Q30364523 | Pre-spillover prevention of emerging zoonotic diseases: what are the targets and what are the tools? |
| Q98771627 | Prospects for RNAi Therapy of COVID-19 |
| Q36944914 | RNA interference and antiviral therapy. |
| Q36508943 | RNA interference for antiviral therapy |
| Q39010088 | RNA interference targeting nucleocapsid protein inhibits porcine reproductive and respiratory syndrome virus replication in Marc-145 cells |
| Q37333053 | RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy |
| Q40501127 | RNA interference-mediated virus clearance from cells both acutely and chronically infected with the prototypic arenavirus lymphocytic choriomeningitis virus |
| Q90666994 | Screening efficient siRNAs in vitro as the candidate genes for chicken anti-avian influenza virus H5N1 breeding |
| Q91901502 | Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) |
| Q28383088 | Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection |
| Q50527698 | Silencing of HTLV-1 gag and env genes by small interfering RNAs in HEK 293 cells. |
| Q99622922 | The "Perfect Cytokine Storm" of COVID-19 |
| Q36435632 | The future of antisense oligonucleotides in the treatment of respiratory diseases |
| Q34015988 | The spike protein of SARS-CoV--a target for vaccine and therapeutic development |
| Q36722338 | Therapeutic and prophylactic potential of small interfering RNAs against severe acute respiratory syndrome: progress to date |
| Q37481314 | Therapies for coronaviruses. Part 2: Inhibitors of intracellular life cycle. |
| Q96128656 | Three kinds of treatment with Homoharringtonine, Hydroxychloroquine or shRNA and their combination against coronavirus PEDV in vitro |
| Q36886595 | Towards our understanding of SARS-CoV, an emerging and devastating but quickly conquered virus |
| Q39907969 | Transient inhibition of foot-and-mouth disease virus replication by siRNAs silencing VP1 protein coding region |
| Q39986579 | siRNA silencing of angiotensin-converting enzyme 2 reduced severe acute respiratory syndrome-associated coronavirus replications in Vero E6 cells. |
| Q40115634 | siRNAs targeting terminal sequences of the SARS-associated coronavirus membrane gene inhibit M protein expression through degradation of M mRNA. |
Search more.